Literature DB >> 4853719

Potent bronchoconstrictor activity of 15-keto prostaglandin F2alpha.

W Dawson, R L Lewis, R E McMahon, W J Sweatman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4853719     DOI: 10.1038/250331a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  11 in total

1.  Actions of prostaglandins on the arterial system of the sheep: some structure-activity relationships.

Authors:  R L Jones
Journal:  Br J Pharmacol       Date:  1975-03       Impact factor: 8.739

2.  Comparative bioassay of prostaglandin E2 and its three pulmonary metabolites.

Authors:  D J Crutchley; P J Piper
Journal:  Br J Pharmacol       Date:  1975-07       Impact factor: 8.739

3.  The effect of pulmonary metabolites of prostaglandins E1, E2 and F2alpha on ADP-induced aggregation of human and rabbit platelets [proceedings].

Authors:  J Westwick
Journal:  Br J Pharmacol       Date:  1976-10       Impact factor: 8.739

4.  Purification, cDNA cloning and expression of 15-oxoprostaglandin 13-reductase from pig lung.

Authors:  C M Ensor; H Zhang; H H Tai
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

5.  Actions of prostaglandin E2 metabolites on skin microcirculation.

Authors:  W P Kingston; M W Greaves
Journal:  Agents Actions       Date:  1985-03

Review 6.  Formation and degradation of prostaglandins in the lung.

Authors:  E Anggard; E Oliw
Journal:  Agents Actions       Date:  1976-07

7.  Release of active substances during anaphylaxis.

Authors:  P J Piper
Journal:  Agents Actions       Date:  1976-07

8.  Immunological and non-immunological mechanisms of some of the desirable and undesirable effects of anti-inflammatory and analgesic drugs.

Authors:  E S Assem
Journal:  Agents Actions       Date:  1976-02

Review 9.  Prostaglandins, thromboxanes and leukotrienes in clinical medicine.

Authors:  R D Zipser; G Laffi
Journal:  West J Med       Date:  1985-10

10.  The pharmacology of isamoxole [2-methyl-n-butyl-n(4-methyloxazol-2-yl) propanamide] LRCL 3950, a new anti-allergic compound.

Authors:  W Dawson; W J Sweatman
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.